Canadian Banc Corp. Monthly Dividend Declaration for Class A & Preferred Share

TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- Canadian Banc Corp. (The "Company") declares its monthly distribution of $0.18588 for each Class A share and $0.04958 for each Preferred share. Distributions are payable June 10, 2026 to shareholders on record as at May 29, 2026.

Under the distribution policy announced in November 2021, the monthly dividend payable on the Class A shares is determined by applying a 15% annualized rate on the volume weighted average market price (VWAP) of the Class A shares over the last 3 trading days of the preceding month. As a result, Class A shareholders of record on May 29, 2026 will receive a dividend of $0.18588 per share based on the VWAP of $14.87 payable on June 10, 2026. The yield will remain stable at 15.00% (based on the VWAP) under this distribution policy.

Preferred shareholders will receive prime plus 1.50% with a minimum rate of 5.00% and a maximum rate of 8.00%.

Since inception Class A shareholders have received a total of $25.84 per share and Preferred shareholders have received a total of $11.78 per share inclusive of this distribution, for a combined total of $37.62.

The Company invests primarily in a portfolio of six publicly traded Canadian Banks as follows: Bank of Montreal, Canadian Imperial Bank of Commerce, National Bank of Canada, Royal Bank of Canada, Bank of Nova Scotia, Toronto-Dominion Bank. Shares held within the portfolio are expected to range between 5- 20% in weight but may vary at any time. To generate additional returns above the dividend income earned on the portfolio, The Company engages in a selective covered call writing program.

You May Also Be Interested In

• Lifestyle Expert Christine Bibbo Herr Discusses Tips for a Healthy Summer Shift with YourUpdateTV
• Onchain Trading Boom Is Exposing a Costly Infrastructure Gap, Bitget Wallet Data Shows
• US WorldMeds® Receives Full U.S. FDA Approval of TECELRA® (afamitresgene autoleucel) with an Expanded Indication, Extending the First Approved Engineered T-Cell Therapy for a Solid Tumor to Children